A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Trial details
- Registry ID
- NCT07365319
- Drugs studied
- EIK1001, Nab-paclitaxel + Carboplatin, Paclitaxel + Carboplatin, Pembrolizumab (KEYTRUDA®) and 1 more